Proprietary Platform Technology Promising Broad-Spectrum Antimicrobial Activity, Initiate with a Buy-Extended Rating. Strong revenue growth of Travelan®, Immuron’s OTC commercial product to treat and reduce the risk of contracting travelers’ diarrhea, an innovative platform technology addressing large unmet medical needs, and name brand research partnerships are driving momentum. Near-term clinical milestones add interest to the IMRN narrative.
